Lv11
10 积分 2025-02-27 加入
Administering [177Lu]Lu-PSMA-617 Prior to Radical Prostatectomy in Men with High-risk Localised Prostate Cancer (LuTectomy): A Single-centre, Single-arm, Phase 1/2 Study
3小时前
待确认
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial
7天前
已完结
Noninvasive prognostic classification of ITH in HCC with multi-omics insights and therapeutic implications
1个月前
已完结
Non‐Invasive Tumor Budding Evaluation and Correlation with Treatment Response in Bladder Cancer: A Multi‐Center Cohort Study
1个月前
已关闭
Circulating tumor DNA in early-stage triple-negative breast cancer: clinical landscape and key open challenges
2个月前
已完结
Role of circulating tumor DNA in early-stage triple-negative breast cancer: a systematic review and meta-analysis
2个月前
已完结
Role of circulating tumor DNA in early-stage triple-negative breast cancer: a systematic review and meta-analysis
2个月前
已关闭
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial
2个月前
已完结
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial
2个月前
已关闭
Incorporating the [68Ga]Ga-PSMA PET/CT PRIMARY score into the selection criteria for prostate cancer patients eligible for active surveillance
2个月前
已完结
皖公网安备34019202002308
